Data Year:

For its 2025 fiscal year, PROTHENA CORPORATION PLC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Tran B. Nguyen
Chief Strategy Officer and Chief Financial Officer
Total Compensation $2,661,109 View details Pay Rank By Title In Biotechnology industry #183 View more
Gene G. Kinney Ph.D.
President and Chief Executive Officer
Total Compensation $5,896,045 View details Pay Rank By Title In Biotechnology industry #232 View more
Wagner M. Zago Ph.D.
Chief Scientific Officer
Total Compensation $2,411,735 View details Pay Rank By Title In Biotechnology industry #29 View more
Brandon S. Smith
Chief Operating Officer
Total Compensation $2,812,044 View details Pay Rank By Title In Biotechnology industry #62 View more
Chad J. Swanson Ph.D.
Chief Dev. Officer
Total Compensation $2,415,159 View details Pay Rank By Title In Biotechnology industry #147 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at PROTHENA CORPORATION PLC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. PROTHENA CORPORATION PLC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. PROTHENA CORPORATION PLC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Tran B. Nguyen
Chief Strategy Officer and Chief Financial Officer
Total Cash $900,584 Equity $1,744,775 Other $15,750 $2,661,109
Gene G. Kinney Ph.D.
President and Chief Executive Officer
Total Cash $1,108,757 Equity $4,771,538 Other $15,750 $5,896,045
Wagner M. Zago Ph.D.
Chief Scientific Officer
Total Cash $719,910 Equity $1,676,075 Other $15,750 $2,411,735
Brandon S. Smith
Chief Operating Officer
Total Cash $811,069 Equity $1,985,225 Other $15,750 $2,812,044
Chad J. Swanson Ph.D.
Chief Dev. Officer
Total Cash $723,334 Equity $1,676,075 Other $15,750 $2,415,159
For its 2025 fiscal year, PROTHENA CORPORATION PLC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Gene G. Kinney Ph.D. CEO Pay $5,896,045 Median Employee Pay $417,917 CEO Pay Ratio 14:1
For its 2024 fiscal year, PROTHENA CORPORATION PLC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Daniel G. Welch Total Cash $2,667,688
Dennis J. Selkoe Total Cash $297,937
Helen S. Kim Total Cash $288,007
K. Anders O. Härfstrand Total Cash $27,295
Lars G. Ekman Total Cash $304,851
Paula K. Cobb Total Cash $304,346
Richard T. Collier Total Cash $302,641
Shane M. Cooke Total Cash $309,958
William H. Dunn, Jr. Total Cash $288,437
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.